文献速递头颈部肿瘤放疗

局部晚期鼻咽癌诱导化疗后缩小IMRT靶区的前瞻性多中心随机临床试验治疗结局

Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
PubMed 文献 · Radiother Oncol · 2017-08-29

该前瞻性多中心随机试验将212例III-IVb期鼻咽癌患者随机分为A组(n=97,基于诱导化疗前图像制定IMRT计划)和B组(n=115,基于诱导化疗后图像制定IMRT计划),所有患者接受诱导化疗后顺铂同步IMRT。结果显示B组正常组织受量更低(P<0.05),口干症状恢复及生活质量评分更优,中位随访35个月时两组1年、2年、3年OS、PFS、LRFFS、DMFS均无显著差异。结论认为诱导化疗后缩小IMRT靶区不降低局部控制和生存率,同时降低正常组织受量并改善生活质量。

要点

  • 诱导化疗后缩小IMRT靶区不降低局部控制和生存率。
  • 缩小靶区可降低正常组织受量(P<0.05)并改善口干症状恢复。
  • B组生活质量评分高于A组。

核心结论

  • 局部晚期鼻咽癌诱导化疗后缩小IMRT靶区不降低局部控制率和生存率,且降低正常组织受量并改善生活质量评分。

研究设计与样本

  • 前瞻性多中心随机临床试验纳入212例III-IVb期鼻咽癌患者,随机分为A组(n=97,基于诱导化疗前图像制定IMRT计划)和B组(n=115,基于诱导化疗后图像制定IMRT计划),均接受诱导化疗后顺铂同步IMRT。

主要发现

  • B组正常组织受量低于A组(P<0.05)。
  • B组口干症状恢复显著优于A组,生活质量评分高于A组。
  • 2年OS 93.7% vs 92.9%、PFS 83.4% vs 84.3%、LRFFS 96.8% vs 95.5%、DMFS 86.5% vs 89.5%。
  • 3年OS 82.3% vs 87%、PFS 74.7% vs 83.4%、LRFFS 91.8% vs 93.9%、DMFS 81.3% vs 88.6%。

临床怎么用

  • 对于局部晚期鼻咽癌,诱导化疗后基于化疗后图像缩小IMRT靶区可在不牺牲肿瘤控制的前提下减少正常组织照射并改善患者生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate whether reducing the target volume of intensity-modulated radiotherapy (IMRT) after induction chemotherapy (IC) improves the quality of life (QOL) in locoregionally advanced nasopharyngeal carcinoma (NPC) without decreasing the local control and survival rate. PATIENTS AND METHODS: A total number of 212 NPC patients staged as III-IVb were randomly assigned to group A (n=97) or group B (n=115) in this prospective clinical trial. All patients received IC followed by cisplatin concurrent with IMRT. IMRT was planned using the images of pre-IC in group A and post-IC in group B. RESULTS: The dose received by normal tissues in group B was lower than that of group A (P<0.05). The recovery of the dry mouth symptoms in group B was significantly improved than group B. The quality of life (QOL) scores in group B were higher than group A. With a median follow-up of 35months, the 1-year estimated overall survival (OS), progression-free survival (PFS), locoregional failure-free survival (LRFFS), distant metastasis-free survival (DMFS) in group A versus group B were 97.9% vs 97.3%, 90.7% vs 92,2%, 99.0% vs 98.2%, 91.8% vs 94.8%. The 2-year OS, PFS, LRFFS, DMFS in group A versus group B were 93.7% vs 92.9%, 83.4% vs 84.3%, 96.8% vs 95.5%, 86.5% vs 89.5%. The 3-year OS, PFS, LRFFS, DMFS in group A versus group B were 82.3% vs 87%, 74.7% vs 83.4%, 91.8 vs 93.9%, 81.3% vs 88.6%, respectively. CONCLUSION: Reducing the IMRT target volume after IC did not reduce the local control and survival rate in locoregionally advanced NPC but the doses received by normal tissues were decreased, and the QOL scores were improved.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yang H, Chen X, Lin S, et al. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. Radiother Oncol. 2017. PMID: 28864073. doi:10.1016/j.radonc.2017.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。